efgartigimod alfa and hyaluronidase (human recombinant)

CHEBI:CHEBI_754415

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

rxcui
2639957
product_type
HUMAN PRESCRIPTION DRUG
listing_expiration_date
20251231
dosage_form
INJECTION, SOLUTION
route
SUBCUTANEOUS
marketing_start_date
20230620
package_marketing_start_date
20230620
marketing_category
BLA
active_ingredient_strength
2000 U/mL
active_ingredient_name
HYALURONIDASE (HUMAN RECOMBINANT)
unii
961YV2O515
nui
N0000194005
pharm_class_epc
Neonatal Fc Receptor Blocker [EPC]
pharm_class
Neonatal Fc Receptor Blockers [MoA]
pharm_class_cs
Glycoside Hydrolases [CS]
pharm_class_moa
Neonatal Fc Receptor Blockers [MoA]
labeler_name
argenx US
manufacturer_name
argenx US
generic_name
efgartigimod alfa and hyaluronidase (human recombinant)
brand_name
VYVGART Hytrulo
brand_name_base
VYVGART Hytrulo
product_ndc
73475-3102
application_number
BLA761304
spl_id
4ff4519c-ae5e-482a-90c1-0d3912cc6fc5
package_ndc
73475-3102-3
package_description
1 VIAL, SINGLE-DOSE in 1 CARTON (73475-3102-3) / 5.6 mL in 1 VIAL, SINGLE-DOSE
spl_set_id
7104d9e5-9910-47f5-9a93-741ac50f43b6
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class